RxDoctor Payments Data

Ashwini Sharma, MD

Interventional Cardiology · Montgomery, ALNPI 1386085793

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (54.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 44.8% of the total. Reporting peaked in 2023 at $4,180 and has fallen 88.3% since, to $490 in 2025.

$8,042in general payments, 2019–2025

Across 135 payments — averaging $59.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Edwards Lifesciences$3K
  • Novartis$378
  • Amgen$253
  • Pfizer$227
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$190
  • plus $743 from 16 others

What the payments were for

  • Travel & lodging$4,38254%
  • Food & beverage$3,64645%
  • Education$140%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,042 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$268,520
Medicare patients
1,205
Services billed
3,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban286$323,073
VyndamaxTafamidis21$231,483
EntrestoSacubitril/Valsartan137$144,719
Repatha SureclickEvolocumab127$104,351
XareltoRivaroxaban99$96,704
MultaqDronedarone Hcl35$48,690
FarxigaDapagliflozin Propanediol22$26,334
BrilintaTicagrelor38$24,402
Rosuvastatin Calcium290$8,036
Atorvastatin Calcium481$7,156
Ranolazine ErRanolazine61$6,679
Metoprolol Succinate384$6,356
Carvedilol372$4,204
Amiodarone Hcl58$3,733
ClopidogrelClopidogrel Bisulfate243$3,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$227$554,556307 claims
NovartisEntresto$378$144,719137 claims
Johnson & JohnsonXarelto$23$96,70499 claims
AstraZenecaFarxiga, Brilinta$14$50,73660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →